Literature DB >> 31776292

Early antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and induces a distinct innate immune profile.

Pilar Garcia-Broncano1, Shivaali Maddali1, Kevin B Einkauf1,2, Chenyang Jiang1,2, Ce Gao1, Joshua Chevalier1,2, Fatema Z Chowdhury1, Kenneth Maswabi3, Gbolahan Ajibola3, Sikhulile Moyo3, Terence Mohammed3, Thabani Ncube3, Joseph Makhema3, Patrick Jean-Philippe4, Xu G Yu1,2,5, Kathleen M Powis3,5,6,7, Shahin Lockman2,3,5, Daniel R Kuritzkes2,5, Roger Shapiro3,5,7, Mathias Lichterfeld8,2,5.   

Abstract

Neonatal HIV-1 infection is associated with rapidly progressive and frequently fatal immune deficiency if left untreated. Immediate institution of antiretroviral therapy (ART), ideally within hours after birth, may restrict irreversible damage to the developing neonatal immune system and possibly provide opportunities for facilitating drug-free viral control during subsequent treatment interruptions. However, the virological and immunological effects of ART initiation within hours after delivery have not been systematically investigated. We examined a unique cohort of neonates with HIV-1 infection from Botswana who started ART shortly after birth and were followed longitudinally for about 2 years in comparison to control infants started on treatment during the first year after birth. We demonstrate multiple clear benefits of rapid antiretroviral initiation, including an extremely small reservoir of intact proviral sequences, a reduction in abnormal T cell immune activation, a more polyfunctional HIV-1-specific T cell response, and an innate immune profile that displays distinct features of improved antiviral activity and is associated with intact proviral reservoir size. Together, these data offer rare insight into the evolutionary dynamics of viral reservoir establishment in neonates and provide strong empirical evidence supporting the immediate initiation of ART for neonates with HIV-1 infection.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31776292      PMCID: PMC8397898          DOI: 10.1126/scitranslmed.aax7350

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  64 in total

1.  Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy.

Authors:  Peter W Hunt; Huyen L Cao; Conrad Muzoora; Isaac Ssewanyana; John Bennett; Nneka Emenyonu; Annet Kembabazi; Torsten B Neilands; David R Bangsberg; Steven G Deeks; Jeffrey N Martin
Journal:  AIDS       Date:  2011-11-13       Impact factor: 4.177

2.  Post-treatment control in an adult with perinatally acquired HIV following cessation of antiretroviral therapy.

Authors:  James H McMahon; Judy Chang; Surekha Tennakoon; Ashanti Dantanarayana; Ajantha Solomon; Catherine Cherry; Richard Doherty; Paul Cameron; Sharon R Lewin
Journal:  AIDS       Date:  2017-06-01       Impact factor: 4.177

Review 3.  Very early combination antiretroviral therapy in infants: prospects for cure.

Authors:  Kaitlin Rainwater-Lovett; Katherine Luzuriaga; Deborah Persaud
Journal:  Curr Opin HIV AIDS       Date:  2015-01       Impact factor: 4.283

4.  Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers.

Authors:  Asier Sáez-Cirión; Chiraz Hamimi; Anna Bergamaschi; Annie David; Pierre Versmisse; Adeline Mélard; Faroudy Boufassa; Françoise Barré-Sinoussi; Olivier Lambotte; Christine Rouzioux; Gianfranco Pancino
Journal:  Blood       Date:  2011-06-03       Impact factor: 22.113

Review 5.  The pharmacological treatment of acute HIV infections in neonates.

Authors:  Louise Kuhn; Stephanie Shiau
Journal:  Expert Rev Clin Pharmacol       Date:  2017-11-03       Impact factor: 5.045

6.  Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study.

Authors:  William T Shearer; Howard M Rosenblatt; Rebecca S Gelman; Rebecca Oyomopito; Susan Plaeger; E Richard Stiehm; Diane W Wara; Steven D Douglas; Katherine Luzuriaga; Elizabeth J McFarland; Ram Yogev; Mobeen H Rathore; Wende Levy; Bobbie L Graham; Stephen A Spector
Journal:  J Allergy Clin Immunol       Date:  2003-11       Impact factor: 10.793

7.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

8.  Non-Classical monocytes display inflammatory features: Validation in Sepsis and Systemic Lupus Erythematous.

Authors:  Ratnadeep Mukherjee; Pijus Kanti Barman; Pravat Kumar Thatoi; Rina Tripathy; Bidyut Kumar Das; Balachandran Ravindran
Journal:  Sci Rep       Date:  2015-09-11       Impact factor: 4.379

9.  Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics.

Authors:  Nina N Hosmane; Kyungyoon J Kwon; Katherine M Bruner; Adam A Capoferri; Subul Beg; Daniel I S Rosenbloom; Brandon F Keele; Ya-Chi Ho; Janet D Siliciano; Robert F Siliciano
Journal:  J Exp Med       Date:  2017-03-24       Impact factor: 14.307

10.  HIV-1 DNA sequence diversity and evolution during acute subtype C infection.

Authors:  Guinevere Q Lee; Kavidha Reddy; Kevin B Einkauf; Kamini Gounder; Joshua M Chevalier; Krista L Dong; Bruce D Walker; Xu G Yu; Thumbi Ndung'u; Mathias Lichterfeld
Journal:  Nat Commun       Date:  2019-06-21       Impact factor: 14.919

View more
  37 in total

1.  Longitudinal Dynamics of Intact HIV Proviral DNA and Outgrowth Virus Frequencies in a Cohort of Individuals Receiving Antiretroviral Therapy.

Authors:  Shane D Falcinelli; Kayla W Kilpatrick; Jenna Read; Ross Murtagh; Brigitte Allard; Simon Ghofrani; Jennifer Kirchherr; Katherine S James; Erin Stuelke; Caroline Baker; JoAnn D Kuruc; Joseph J Eron; Michael G Hudgens; Cynthia L Gay; David M Margolis; Nancie M Archin
Journal:  J Infect Dis       Date:  2021-07-02       Impact factor: 5.226

Review 2.  The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies.

Authors:  Lillian B Cohn; Nicolas Chomont; Steven G Deeks
Journal:  Cell Host Microbe       Date:  2020-04-08       Impact factor: 21.023

3.  Capitalizing on Postexposure Antiretroviral Prophylaxis to Restrict Seeding of the Human Immunodeficiency Virus Reservoir.

Authors:  Adit Dhummakupt; Deborah Persaud
Journal:  Clin Infect Dis       Date:  2021-08-02       Impact factor: 9.079

4.  Differences in inducibility of the latent HIV reservoir in perinatal and adult infection.

Authors:  Adit Dhummakupt; Jessica H Rubens; Thuy Anderson; Laura Powell; Bareng As Nonyane; Lilly V Siems; Aleisha Collinson-Streng; Tricia Nilles; R Brad Jones; Vicki Tepper; Allison Agwu; Deborah Persaud
Journal:  JCI Insight       Date:  2020-02-27

Review 5.  The HIV-1 antibody response: a footprint of the viral reservoir in children vertically infected with HIV.

Authors:  Paolo Palma; Margaret McManus; Nicola Cotugno; Salvatore Rocca; Paolo Rossi; Katherine Luzuriaga
Journal:  Lancet HIV       Date:  2020-05       Impact factor: 12.767

6.  Human Hematopoietic Stem Cell (HSC)-Engrafted NSG Mice for HIV Latency Research.

Authors:  Triana Rivera-Megias; Nhut M Le; Alonso Heredia
Journal:  Methods Mol Biol       Date:  2022

7.  Initiation of Antiretroviral Therapy during Primary HIV Infection: Effects on the Latent HIV Reservoir, Including on Analytic Treatment Interruptions.

Authors:  Eva M Shelton; Daniel B Reeves; Rachel A Bender Ignacio
Journal:  AIDS Rev       Date:  2020-10-26       Impact factor: 2.500

8.  T cell immune discriminants of HIV reservoir size in a pediatric cohort of perinatally infected individuals.

Authors:  Stefano Rinaldi; Lesley de Armas; Sara Dominguez-Rodríguez; Suresh Pallikkuth; Vinh Dinh; Li Pan; Kathleen Gӓrtner; Rajendra Pahwa; Nicola Cotugno; Pablo Rojo; Eleni Nastouli; Nigel Klein; Caroline Foster; Anita De Rossi; Carlo Giaquinto; Paolo Rossi; Paolo Palma; Savita Pahwa
Journal:  PLoS Pathog       Date:  2021-04-26       Impact factor: 6.823

9.  Detection of Inducible Replication-Competent HIV-1 Subtype C Provirus Despite Long-Term Antiretroviral Treatment in Perinatally Infected Adolescents in Botswana.

Authors:  Catherine K Koofhethile; Sikhulile Moyo; Kenanao P Kotokwe; Charlotte Chang; Patrick Mokgethi; Lorato Muchoba; Selebogo Mokgweetsi; Joseph Makhema; Shahin Lockman; Simani Gaseitsiwe; Tulio de Oliveira; M Essex; Roger Shapiro; Phyllis Kanki; Vladimir Novitsky
Journal:  AIDS Res Hum Retroviruses       Date:  2020-10-19       Impact factor: 2.205

10.  Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study.

Authors:  Theodore D Ruel; Edmund V Capparelli; Camlin Tierney; Bryan S Nelson; Anne Coletti; Yvonne Bryson; Mark F Cotton; Stephen A Spector; Mark Mirochnick; Rebecca LeBlanc; Christina Reding; Bonnie Zimmer; Deborah Persaud; Mutsa Bwakura-Dangarembizi; Kimesh L Naidoo; Rohan Hazra; Patrick Jean-Philippe; Ellen G Chadwick
Journal:  Lancet HIV       Date:  2020-11-23       Impact factor: 12.767

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.